THANK YOU FOR SUBSCRIBING
Surge's technology is capable of predicting postoperative complications before they occur
FREMONT, CA: "At Boutique, we are thrilled to partner with Surge's team to help decode immune fingerprints to accurately identify patients at risk before surgery. What impresses us most about Surge is the ability to integrate a proprietary machine-learning algorithm with single-cell and plasma proteomic data to predict surgical complications, including infection and cognitive decline. We were familiar with Dr. Gaudillière's work at Stanford (before even meeting him) and his approach of using the power of single-cell mass cytometry (CyTOF) to identify immune dysfunction that drives pathological stressors". – Dr. Rami El Assal, Managing General Partner & Co-founder of Boutique Venture Partners.
The San Francisco-based biotech and medical AI startup Surge has raised $2.6 million from HCVC. A global early-stage fund focused on high-potential technology companies. Angel investors, including Cardiologs COO/CFO Nicolas Godin, participated in the round. A 2022 iLab grant was awarded to Surge and other non-dilutive grants.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
In the US, Surge is hosted by StartX, a nonprofit founders community; in Europe, it is supported by Agoranov, 50 Partners, and Wilco. Physicians can forecast postoperative complications quickly with this technology. Surge's solution enables targeted and personalized interventions to reduce patients' risk of postsurgical complications, with 30 percent of major surgeries currently resulting in complications and 40 percent suffering long-lasting cognitive impacts after orthopedic or cardiac surgery.
"We are proud to support Surge in its ambition to reduce the risk of postoperative complications. Its international, multidisciplinary team inspires respect. They have created very strong relationships spanning both the French and American academic worlds, with partners including AP-HP, and Institut Pasteur, and Stanford building a solid network that will allow them to achieve their goals." -Alexis Houssou, founder of HCVC Partners.
With Surge's technology, the immune system is analyzed biologically, and an AI algorithm is used to predict surgical complications and recommend customized prevention strategies.
"Our ambition is to develop the reference solution for surgical precision medicine. We plan to expand and diversify the applications of our technology with immune profiling tools for all surgical complications. Eventually, we also want to apply our methodology to other therapeutic areas." -said Julien Hédou, President and Co-founder of Surge.
More in News